Numab offers its cutting-edge discovery engine to partners looking to develop innovative antibody-based therapeutics with multiple specificities, tailored half-lives, unrivaled potency, and ready to be taken into preclinical and process development. Our disclosed partners are 3SBio/Sunshine Guojian, Boehringer Ingelheim, Eisai, CStone, Ono, Kaken, and Tillotts.